Dan Burgess

Daniel Burgess joined SV Life Sciences as a Venture Partner in 2014.

Prior to joining SV, Mr. Burgess was founder, President and CEO of Rempex Pharmaceuticals, Inc. (SVLS Fund V), an antibiotic company that was sold to the Medicines Company two years after its founding in a transaction valued at up to $475 million. Previously Mr. Burgess was President and CEO of Mpex Pharmaceuticals, Inc. (SVLS Fund IV), a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials before it was acquired by Aptalis, Inc. in 2011. Mr. Burgess has also held senior executive positions at a number of other biotechnology companies and served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion.

Mr. Burgess received an AB in Economics from Stanford University and an MBA from Harvard Business School.

Dan Burgess is the Venture Partner at SV Health Investors, based in United States, North America. With a background in Venture Capital, Dan Burgess has a rich history of leadership and innovation. Dan Burgess studied MBA Business @ Harvard Business School. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.